Environmental, Social and Governance Report

The report describes Sino Biopharmaceutical's 2025 ESG governance, including a double materiality assessment, a carbon neutrality action plan and company-wide climate governance. It reports Scope 1, Scope 2 and partial Scope 3 emissions, expanded renewable energy use, and a workforce of 23,826 employees. The report also highlights continued R&D investment, healthcare accessibility initiatives and employee development.